Zepbound® for weight loss
Brand-name tirzepatide, FDA-approved for chronic weight management.
Zepbound® is Eli Lilly's brand-name injectable tirzepatide. A Temi clinician can prescribe it when clinically appropriate — the brand is dispensed through Eli Lilly's LillyDirect pharmacy, not by Temi.
Zepbound® self-pay prices
These are LillyDirect self-pay reference prices by weekly dose, set by Lilly.
2.5 mg/week
$299/mo
5 mg/week
$399/mo
7.5 mg/week
$449/mo
10 mg/week
$449/mo
12.5 mg/week
$449/mo
15 mg/week
$449/mo
Product details
- Active ingredient
- Tirzepatide
- Manufacturer
- Eli Lilly and Company
- Drug class
- GIP and GLP-1 receptor agonist
- Form
- Injectable (subcutaneous), once weekly
- Available doses
- 2.5–15 mg per week
- Dispensed by
- LillyDirect pharmacy
About Zepbound®
Zepbound® (tirzepatide) is a once-weekly injection, FDA-approved alongside a reduced-calorie diet and increased physical activity to help adults with obesity — or adults with overweight and at least one weight-related condition — lose excess weight and keep it off. It is also FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.1
How it works. Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two gut-hormone receptors — GIP and GLP-1 — that influence appetite, fullness, and how the body handles food, which can help you eat less.1
- A once-weekly injection you take under the skin.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist.
- FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
Dosing and titration
A clinician sets your dose. The label's schedule starts low and steps up gradually to help limit side effects.1
- Weeks 1–4
- 2.5 mg once weekly
- Weeks 5–8
- 5 mg once weekly
- Then, no sooner than every 4 weeks
- Increase by 2.5 mg
- Maximum dose
- 15 mg once weekly
The 2.5 mg dose is for starting treatment and is not a maintenance dose. The recommended maintenance doses are 5, 10, or 15 mg once weekly (5 mg for weight management only). Doses increase no sooner than every 4 weeks.1
What the studies show
In SURMOUNT-1 — a 72-week trial of 2,539 adults with obesity or overweight (without type 2 diabetes) — average body-weight reduction, alongside a reduced-calorie diet and increased physical activity, was:23
- 5 mg dose
- 16.0%
- 10 mg dose
- 21.4%
- 15 mg dose
- 22.5%
- Placebo
- 2.4%
In separate trials (SURMOUNT-OSA), tirzepatide reduced the number of breathing interruptions per hour in adults with moderate-to-severe obstructive sleep apnea and obesity.4
These are trial averages. Individual results vary with dose, health history, diet, and exercise, and weight loss is not guaranteed.
Common questions
Does Temi sell Zepbound®?
No. A Temi clinician can prescribe branded Zepbound® when it is clinically appropriate, but Temi does not sell or dispense it. If prescribed, it is filled through Eli Lilly's LillyDirect pharmacy, and you pay LillyDirect's self-pay price.
What is tirzepatide?
Tirzepatide is the active ingredient in Zepbound®. It is a dual GIP and GLP-1 receptor agonist — it acts on two gut-hormone pathways that influence appetite, fullness, and how the body handles food.
How is Zepbound® taken?
It is a once-weekly injection under the skin, on the same day each week, with or without food. Your prescriber sets your starting dose and any step-ups in dose over time.
Who should not take Zepbound®?
It is not for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or anyone who has had a serious allergic reaction to tirzepatide. Your clinician reviews your full history before prescribing.
How much does Zepbound® cost?
Pricing is set by Eli Lilly's LillyDirect pharmacy, not by Temi. See the self-pay reference prices above; they are set by Lilly and may change.
Talk to a Temi clinician about your options
A licensed clinician can review your history and help you decide what fits — including FDA-approved brand options like Zepbound®.
Sources
- 1.ZEPBOUND® (tirzepatide) Prescribing Information. Eli Lilly and Company.
- 2.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
- 3.Eli Lilly and Company. SURMOUNT-1 results: tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight.
- 4.Eli Lilly and Company. FDA approves Zepbound® for moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024).